Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05131022 · ClinicalTrials.gov registry record · Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
A Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by Nurix Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 572
- Enrollment target
- 20
- Study locations
NCT05131022: Recruiting Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by Nurix Therapeutics.
NCT05131022 is a Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) that is actively recruiting participants, run by Nurix Therapeutics. The registered enrollment target is 572 participants, above the 172-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (233% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05131022, a Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), is actively recruiting participants, sponsored by Nurix Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 572 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
Primary Outcome
Phase 1a
Conditions Studied
Interventions
- DRUG NX-5948
Study Locations (20)
California
- City of Hope - Duarte
- University of California, San Francisco - San Francisco
Florida
- University of Miami - Miami
- Florida Cancer Specialists - Sarasota
New York
- Cayuga Medical Center - Ithaca
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- University of Cincinnati Medical Center - Cincinnati
- Cleveland Clinic - Cleveland
Other
- CHU Angers - Angers
- Hôpital Avicenne - Bobigny
Colorado
- Colorado Blood Cancer Institute - Denver
Connecticut
- Yale Cancer Center - New Haven
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 572 participants |
| Start Date | 2022-04-13 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
What NCT05131022 shows while recruiting
NCT05131022 is an interventional study that assigns participants to a tested intervention. The registered 572 participants enrollment target is mid-sized for trials with a published cap, above the 172-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (233% higher).
The record links to 9 conditions, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 1 intervention - of which NX-5948 is the first listed.
NCT05131022 names 20 study sites across 15 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT05131022 about?
NCT05131022 is a clinical study titled "A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies". This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
What is the current status of trial NCT05131022?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 572 participants. The study started on 2022-04-13. Estimated completion is 2028-01.
What conditions does trial NCT05131022 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL).
What interventions are being tested in trial NCT05131022?
The interventions under investigation include: NX-5948 (DRUG).
Who is sponsoring clinical trial NCT05131022?
This trial is sponsored by Nurix Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05131022 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia (CLL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05131022's enrollment target sits among peer trials
572 3rd of 29 higher than 27 of 29 other Chronic Lymphocytic Leukemia (CLL) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia (CLL) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
RECRUITING · Phase 1
-
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
ACTIVE NOT RECRUITING · Phase 1
-
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06346392 · 572 participants · Phase 3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
- NCT06615050 · 572 participants · Phase 3
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- NCT07192055 · 572 participants · NA
Self-sampling to Optimize Anal Lesion Outcomes
- NCT05977751 · 573 participants · NA
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI